Clinical Trials
4 trialsNCT03994796 2026-04-13
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05853575 2026-03-27
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Active not recruiting
NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing